Y-mAbs Therapeutics Inc YMAB.OQ YMAB.O is expected to show a rise in quarterly revenue when it reports results on November 8 for the period ending September 30 2024
The New York City-based company is expected to report a 13.7% increase in revenue to $23.263 million from $20.45 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
LSEG's mean analyst estimate for Y-mAbs Therapeutics Inc is for a loss of 16 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Y-mAbs Therapeutics Inc is 21.50, above its last closing price of $15.10.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2024 | -0.13 | -0.13 | -0.21 | Missed | -59.8 |
Mar. 31 2024 | -0.14 | -0.14 | -0.15 | Missed | -10.5 |
Jan. 1 0001 | -0.20 | -0.20 | -0.02 | Beat | 90.1 |
Sep. 30 2023 | -0.18 | -0.19 | -0.18 | Beat | 3.7 |
Jun. 30 2023 | -0.24 | -0.14 | 42.1 | ||
Mar. 31 2023 | -0.32 | -0.32 | -0.15 | Beat | 52.9 |
Dec. 31 2022 | -0.44 | -0.46 | 0.03 | Beat | 106.6 |
Sep. 30 2022 | -0.71 | -0.71 | -0.63 | Beat | 11.3 |
This summary was machine generated November 6 at 14:13 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。